{"groups":[{"description":"Experimental: Patients will receive a single IV injection of 124I-AT-01 radiotracer and PET/CT imaging\n\n124I-AT-01 (124I-p5+14, iodine-124I evuzamitide) is an iodine-124 (124I) labeled 45 L-amino acid peptide suitable for PET/CT imaging. The peptide binds many forms of amyloid through multivalent electrostatic interactions with the amyloid fibril and ubiquitous heparan sulfate proteoglycans.\n\n124I-AT-01 has been evaluated previously in an open-label Phase 1/2 clinical trial, AMY1001, performed at the University of Tennessee Medical Center (IND# 132282; NCT T03678259).\n\nIn this repeat imaging study, patients previously enrolled in the AMY1001 study, in whom positive PET/CT imaging findings were observed will undergo repeat imaging to assess changes in radiotracer uptake in the liver, spleen, heart and kidneys.","id":"FG000","title":"All Participants"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"19"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"19"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Prior to assignment, potential participants were screened to verify their medical records, including confirming that participants must have been imaged with 124I-AT-01 as part of the AMY1001 study more than 12 months prior to the repeat imaging.","recruitmentDetails":"Data of participants diagnosed with systemic AL or ATTR amyloidosis who were previously imaged with 124I-AT-01 as part of the AMY1001 study (NCT03678259) and in whom there was visually positive uptake of radiotracer in at least one abdominothoracic organ."}